- Home
- FDMT vs DMAC Comparison
FDMT vs DMAC Comparison
Compare FDMT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | DMAC |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.6M | 428.6M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FDMT | DMAC |
|---|---|---|
| Price | $8.71 | $7.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $34.13 | $15.50 |
| AVG Volume (30 Days) | ★ 725.8K | 165.4K |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $37,000.00 | ★ $500,000.00 |
| Revenue This Year | $21,227.03 | N/A |
| Revenue Next Year | $161.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $3.22 |
| 52 Week High | $12.34 | $10.42 |
Technical Indicators
Market Signals| Indicator | FDMT | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 42.48 |
| Support Level | $8.11 | $7.32 |
| Resistance Level | $8.80 | $9.01 |
| Average True Range (ATR) | 0.57 | 0.40 |
| MACD | -0.14 | -0.08 |
| Stochastic Oscillator | 20.96 | 29.61 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.